GLP-1 analog liraglutide enhances proinsulin processing in pancreatic β-cells via a PKA-dependent pathway

Endocrinology (United States)

Volumn 155, Issue 10, 2014, Pages 3817-3828

  Wang, Liang ^a   Liu, Ye ^a   Yang, Jin ^a   Zhao, Hejun ^a   Ke, Jing ^a   Tian, Qing ^a   Zhang, Lin ^a   Wen, Jinhua ^b   Wei, Rui ^a   Hong, Tianpei ^a,b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 9 39; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; LIRAGLUTIDE; MESSENGER RNA; PROINSULIN; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; PROPROTEIN CONVERTASE 3; UNCLASSIFIED DRUG; GLUCAGON LIKE PEPTIDE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MIN6 CELL LINE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GLUCAGON-LIKE PEPTIDE 1; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, TRANSGENIC; PROINSULIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84907191530     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1218     Document Type: Article

References (57)

1. Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of-cell function: a meta-analysis. Am J Med Sci. 2009;337:321-328.
2. Pfutzner A, Weber MM, Forst T. A biomarker concept for assessment of insulin resistance,-cell function and chronic systemic inflammation in type 2 diabetes mellitus. Clin Lab. 2008;54:485-490.
3. Goodge KA, Hutton JC. Translational regulation of proinsulin biosynthesis and proinsulin conversion in the pancreatic-cell. Semin Cell Dev Biol. 2000;11:235-242.
4. Smeekens SP, Montag AG, Thomas G, et al. Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc Natl Acad Sci USA. 1992;89:8822-8826.
5. Zhu X, Zhou A, Dey A, et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci USA. 2002;99:10293-10298.
6. Jackson RS, Creemers JW, Farooqi IS, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest. 2003;112:1550-1560.
7. Furuta M, Yano H, Zhou A, et al. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA. 1997;94:6646-6651.
8. Heni M, Haupt A, Schafer SA, et al. Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion. BMC Med Genet. 2010;11:86.
9. Zheng X, Ren W, Zhang S, et al. Association of type 2 diabetes susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) and proinsulin conversion in a Chinese population. Mol Biol Rep. 2012; 39:17-23.
10. Wagner R, Dudziak K, Herzberg-Schafer SA, et al. Glucose-raising genetic variants in MADD and ADCY5 impair conversion of proinsulin to insulin. PLoS One. 2011;6:e23639.
11. Chang YC, Chiu YF, Shih KC, et al.CommonPCSK1 haplotypes are associated with obesity in the Chinese population. Obesity (Silver Spring). 2010;18:1404-1409.
12. Wen JH, Chen YY, Song SJ, et al. Paired box 6 (PAX6) regulates glucose metabolism via proinsulin processing mediated by prohormone convertase 1/3 (PC1/3). Diabetologia. 2009;52:504-513.
13. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113:546-593.
14. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov. 2010;9:267-268.
15. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
16. Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic-cell function and argininestimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008;25:152-156.
17. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27: 1335-1342.
18. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
19. Raz I, Hanefeld M,XuL, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
20. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637.
21. Nakashima K, Shimoda M, Hamamoto S, et al. Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival. Mol Cell Endocrinol. 2012;349:281-288.
22. Wang X, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology. 2001;142:1820-1827.
23. Ozaki N, Shibasaki T, Kashima Y, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol. 2000;2:805-811.
24. Pfutzner A, Forst T. Elevated intact proinsulin levels are indicative of-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone. J Diabetes Sci Technol. 2011;5:784-793.
25. Roder ME, Porte DJ, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1998;83:604-608.
26. Saad MF, Kahn SE, Nelson RG, et al. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1990;70:1247-1253.
27. Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D, Polonsky KS. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab. 1993;76:44-48.
28. Krentz AJ, Clark PM, Cox L, Nattrass M. Hyperproinsulinaemia in impaired glucose tolerance. Clin Sci (Lond). 1993;85:97-100.
29. Humphriss DB, Stewart MW, Berrish TS, et al. Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families. Diabetologia. 1997;40:1185-1190.
30. Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study. Diabetes Care. 2005;28:860-865.
31. Lee YA, Yoo JH, Kim JH, et al. Independent relationships of obesity and insulin resistance with serum proinsulin level in prepubertal children with normal glucose tolerance. Pediatr Diabetes. 2011;12: 235-241.
32. Wengert S, Oeztuerk S, HaenleMM,et al. Association of proinsulin and hepatic steatosis in a random, population-based sample. Eur J Endocrinol. 2013;168:195-202.
33. Walraven I, van 't Riet E, Stehouwer CD, et al. Fasting proinsulin levels are significantly associated with 20 year cancer mortality rates. The Hoorn Study. Diabetologia. 2013;56:1148-1154.
34. Hanefeld M, Haffner SM, Menschikowski M, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract. 2002;55:221-227.
35. Pfutzner A, Derwahl M, Jacob S, et al. Limitations of the HOMA-score for assessment of-cell functionality in interventional trialsresults from the PIOglim study. Diabetes Technol Ther. 2010;12: 599-604.
36. Nagi DK, Ali VM, Yudkin JS. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with noninsulin-dependent (type 2) diabetes mellitus. Diabet Med. 1996;13: 753-757.
37. Hostens K, Ling Z, Van Schravendijk C, Pipeleers D. Prolonged exposure of human-cells to high glucose increases their release of proinsulin during acute stimulation with glucose or arginine. J Clin Endocrinol Metab. 1999;84:1386-1390.
38. Haffner SM, Mykkanen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab. 1994;79:1806-1810.
39. Ramachandran A, Snehalatha C, Satyavani K, Vijay V. Effects of genetic predisposition on proinsulin responses in Asian Indians. Diabetes Res Clin Pract. 1998;41:71-77.
40. Wang J, Chen Y, Yuan Q, Tang W, Zhang X, Osei K. Control of precursor maturation and disposal is an early regulative mechanism in the normal insulin production of pancreatic-cells. PLoS One. 2011;6:e19446.
41. Lindgren FA, Hartling SG, Persson BE, et al. Proinsulin levels in newborn siblings of type 1 (insulin-dependent) diabetic children and their mothers. Diabetologia. 1993;36:560-563.
42. Park YJ,AoZ, Kieffer TJ, et al. The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia. 2013;56:508-519.
43. Ugleholdt R, Zhu X, Deacon CF, Orskov C, Steiner DF, Holst JJ. Impaired intestinal proglucagon processing in mice lacking prohormone convertase. Endocrinology. 2004;145:1349-1355
44. Alarcon C, Verchere CB, Rhodes CJ. Translational control of glucose-induced islet amyloid polypeptide production in pancreatic islets. Endocrinology. 2012;153:2082-2087.
45. Mannucci E, Dicembrini I. Incretin-based therapies and cardiovascular risk. Curr Med Res Opin. 2012;28:715-721.
46. Oho C, Seino S, Takahashi M. Expression and complex formation of soluble N-ethyl-maleimide-sensitive factor attachment protein (SNAP) receptors in clonal rat endocrine cells. Neurosci Lett. 1995; 186:208-210.
47. Thorens B, Deriaz N, Bosco D, et al. Protein kinase A-dependent phosphorylation ofGLUT2in pancreatic cells. J Biol Chem. 1996; 271:8075-8081.
48. Beguin P, Nagashima K, Nishimura M, Gonoi T, Seino S. PKAmediated phosphorylation of the human K(ATP) channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation.EMBOJ. 1999; 18:4722-4732.
49. Kawasaki H, Springett GM, Mochizuki N, et al. A family of cAMPbinding proteins that directly activate Rap1. Science. 1998;282: 2275-2279.
50. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci. 2006;31:680-686.
51. Bode HP, Moormann B, Dabew R, Goke B. Glucagon-like peptide 1 elevates cytosolic calcium in pancreatic-cells independently of protein kinase A. Endocrinology. 1999;140:3919-3927.
52. Ishihara H, Asano T, Tsukuda K, et al. Pancreatic cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia. 1993;36:1139-1145.
53. Skelly RH, Schuppin GT, Ishihara H, Oka Y, Rhodes CJ. Glucoseregulated translational control of proinsulin biosynthesis with that of the proinsulin endopeptidases PC2 and PC3 in the insulin-producing MIN6 cell line. Diabetes. 1996;45:37-43.
54. Martin SK, Carroll R, Benig M, Steiner DF. Regulation by glucose of the biosynthesis of PC2, PC3 and proinsulin in (ob/ob) mouse islets of Langerhans. FEBS Lett. 1994;356:279-282.
55. Marchetti P, Lupi R, Bugliani M, et al.Alocal glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012; 55:3262-3272.
56. Whalley NM, Pritchard LE, Smith DM, White A. Processing of proglucagon to GLP-1 in pancreatic-cells: is this a paracrine mechanism enabling GLP-1 to act on-cells? J Endocrinol. 2011;211:99-106.
57. Wideman RD, Yu IL, Webber TD, et al. Improving function and survival of pancreatic islets by endogenous production of glucagonlike peptide 1 (GLP-1). Proc Natl Acad Sci USA. 2006;103:13468-13473.